Compare FPH & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPH | ENTA |
|---|---|---|
| Founded | 2009 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 354.2M | 374.6M |
| IPO Year | 2013 | 2012 |
| Metric | FPH | ENTA |
|---|---|---|
| Price | $4.84 | $12.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.40 |
| AVG Volume (30 Days) | ★ 183.4K | 140.5K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $110,020,000.00 | $102,814,000.00 |
| Revenue This Year | N/A | $7.76 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.40 | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $4.58 | $4.09 |
| 52 Week High | $6.64 | $17.15 |
| Indicator | FPH | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 30.56 | 44.35 |
| Support Level | N/A | $12.09 |
| Resistance Level | $5.71 | $15.52 |
| Average True Range (ATR) | 0.15 | 0.70 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 9.97 | 28.70 |
Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its four reportable segments are Valencia, San Francisco, Great Park, and Hearthstone. It derives the majority of revenue from the Great Park segment, which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.